INTRODUCTION
Genomic tumor analyses over the past decade, exemplified by The Cancer Genome Atlas (TCGA), 1 have greatly enhanced our understanding of the diversity among different types of cancer and among different patients' tumors of the same type. This work has also made it increasingly apparent that cancers are diseases of genetic diversity both among patients and among cancer cells within a single patient's tumor. 2 If a patient's tumor consists of multiple related yet distinct cancers, then we need to reconsider many current approaches in cancer research and therapy. Here, we review the evidence for clinically important diversity both among patients' tumors and within individual tumors, discussing their implications for cancer research and clinical practice.
DIVERSITY AMONG TUMORS

Personalized Therapy and the Search for Common, Targetable Driver Mutations
Much of the motivation for large-scale genomic tumor analysis was to identify "driver" mutations that might provide therapeutic targets. Driver mutations activate oncogenic signaling or inactivate tumor-suppressor pathways, and few drivers are expected in any single tumor. 3 The remarkable success of imatinib in treating chronic myelogenous leukemia and the promising early results with other targeted therapies 4, 5 suggested that identifying new driver genes could allow the development of novel therapies targeting drivers or the pathways they alter, potentially allowing the same agent to be used in different tumor types. 6, 7 In early examples, the protein product of the driver mutation itself (BCR-ABL kinase produced after genomic translocation in chronic myelogenous leukemia; mutated B-Raf proto-oncogene, serine/threonine kinase [BRAF] in melanoma; epidermal growth factor receptor [EGFR] mutated or overexpressed in lung cancer) was the target of therapy. 4 A driver mutation instead may make a tumor highly sensitive to inhibition of a particular cellular function, providing a therapeutic window for tumor-specific attack. For example, DNA repair deficiencies of breast cancer gene (BRCA)-mutant tumors can make them highly sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. 8, 9 Combining genomic analyses of thousands of tumors and cell lines with exhaustive cell-line testing can provide a comprehensive catalog that matches known mutations with drug sensitivity. 10 In principle, if the mutations driving a tumor and how they affect 
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SPOP cellular pathways were known, then a rational choice of patient-specific therapy or combinations of therapies might be possible. 7, 11, 12 Identifying most clinically relevant driver mutations thus is critical for such personalized cancer therapy.
Evaluating the "landscape" of mutations among tumors distinguishes driver mutations from "passenger" mutations that are passively accumulated during tumorigenesis. 13 Genes that are mutated more frequently than by chance among tumors of a particular type, forming peaks in the landscape, are driver mutation candidates. 3, 14 Challenges to Personalized Therapy Although many driver mutations have been identified, genomic analysis of solid tumors has mostly identified foothills in the landscapes of mutations, with few large, highprevalence, targetable peaks. Few genes are altered in greater than 10% of tumors for any type of cancer, and fewer pass that threshold in multiple types of cancer (Table 1). 15 The diversity of driver mutations among tumors and the low prevalence of targetable drivers in solid tumors pose major obstacles to personalized therapy. For example, the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (NCI-MATCH) trial uses mutations in solid tumors or lymphomas to assign patients to particular targeted therapies. Of the first 500 patients enrolled, however, only 9% had targetable mutations identified, and only 33 patients were successfully assigned to a treatment arm; information on how these patients responded is not yet available. 16 Many more driver mutations and the ways in which they affect cellular pathways will need to be identified before personalized cancer therapy is widely available.
Immunotherapy, in principle, provides a way to overcome the challenges from genetic diversity among patients' tumors. Unleashing a patient's immune system to destroy a tumor using patient-specific neoantigens exploits that diversity among tumors, and differences from other patients' tumors should not matter. Even immunotherapy, however, can be limited by the second type of tumor genetic diversity: the diversity that occurs within an individual patient's tumor. 
DIVERSITY WITHIN TUMORS
The challenges posed by diversity within an individual patient's tumor may dwarf those posed by diversity among tumors. Although geographic, phenotypic, and epigenetic diversities also occur, 17, 18 we focus on heritable differences in DNA, intratumor genetic heterogeneity, as the quantifiable type of within-tumor diversity that poses the greatest challenge to therapy.
Subclonal Evolution
Forty years ago, Nowell noted that intratumor evolution through mutation and selection continues after tumor initiation. 19 Cancer cells were already known to have deficiencies in DNA repair, providing higher mutation rates than normal cells. 20 By the time a tumor is clinically detectable, it can be a genetically diverse collection of subclones. Figure 1 illustrates this process. 21 Mutations present in the cell that initiates the tumor clone are "truncal" 22 and are shared by all progeny unless some cells lose that genomic locus. Truncal mutations include drivers, which initiate the tumor, and passengers, which are mutated in the initiating cell but are not responsible for tumor initiation. 3 Mutations in later generations of cells that provide selective survival advantage to a subclone are also driver mutations, whereas other later mutations are passengers. The tumor at presentation thus may contain multiple subclones that differ in their complements of the later mutations.
With subclonal evolution, context can also turn a former passenger mutation into a driver. Some early studies of mouse cancer models were best explained by differences among cancer cells in a tumor. [23] [24] [25] [26] Under Nowell's model, a subclonal mutation might provide resistance to a drug, loss of dependence on a truncal driver mutation, or a tendency to metastasize, favoring some subclones. A "passenger" mutation thus can become a "driver" in the context of tumor progression or therapy.
Measuring Intratumor Genetic Heterogeneity
Next-generation sequencing (NGS) 27 of genomic DNA allows detailed investigation of intratumor genetic heterogeneity. NGS examines millions of individual nucleic acid pieces in parallel, with each piece assessed for mutations at the genomic loci it covers. 28 NGS provides counts of the pieces of DNA covering each genomic locus (sequencing depth) and how many of those pieces exhibit the mutant sequence. The fraction of pieces exhibiting the mutation at a locus is the mutant allele fraction (MAF). Truncal mutations will typically have higher MAF values in a tumor sample than mutations restricted to later developing subclones (Fig. 1) .
NGS of multiple regions of a tumor at adequate sequencing depth to detect subclonal mutations is 1 straightforward approach. Gerlinger et al 29 combined this approach with other analytical methods to establish dramatic differences among geographically distinct portions of renal cell carcinomas. About two-thirds of mutations were not detected across all regions of individual tumors, including some mutations that were potential candidates for targeted therapy.
A single tumor sample can provide information on heterogeneity if the different contributions to MAF values in the sample are taken into account. Besides different MAF values for truncal versus subclonal mutations (Fig.  1) , changes of ploidy from whole-genome duplications and local genomic copy-number aberrations (CNAs) alter MAF values. Furthermore, normal DNA from stromal or immune cells provides an "impurity" that lowers all MAFs below their values in cancer cells per se (Fig. 1) . 30 Several methods to correct for purity, ploidy, and CNAs have been proposed to unravel the subclonal composition of tumors, 31 providing estimates of the fraction of cancer cells with each mutation, the cancer-cell fraction (CCF), which is of major interest in terms of subclonal tumor evolution and potential response to therapy.
To estimate genetic heterogeneity from tumor samples simply without determining subclonal relations, we developed a measure called mutant allele tumor heterogeneity (MATH) (Fig. 2) . 32, 33 MATH incorporates subclonality of point mutations and CNAs at mutated loci while including a first-order correction for tumor "impurity." Heterogeneity measured by MATH may be characteristic of a tumor as a whole, because multiple samples of the same tumor can have similar MATH values, 34 and MATH has been used to demonstrate maintenance of intratumor heterogeneity during passage of patientderived xenografts in mice. 35 Critically, intratumor genetic heterogeneity is not the same as mutation frequency assessed from the number of mutated genomic loci. A tumor with many truncal mutations might not yet have developed subclones. Alternatively, a tumor-initiating clone with few mutations could have evolved into a genetically diverse tumor, even with few late-developing mutations. Indeed, heterogeneity measured by MATH bears little relation to the number of mutated loci in a tumor sample (Fig. 3) . 32, 33 This easily overlooked distinction between mutation numbers and genetic heterogeneity may be particularly important for immunotherapy.
Challenges to Conventional and Targeted Therapy
The clinical risks of high intratumor genetic heterogeneity are no longer just theoretical or restricted to case studies. In head and neck squamous cell carcinoma (HNSCC), high MATH was related to higher mortality in 2 independent data sets totaling nearly 400 patients (Fig. 4) . 32, 36 Among 2433 patients with breast cancer, those who had tumors in the top quartile of MATH values had shorter breast cancer-specific survival than those who had tumors in the bottom quartile. 37 For simplicity, we discuss below the ways that intratumor heterogeneity can affect targeted therapy based on the assumption that a suitable target has been identified. The same principles, however, apply to conventional therapies and should help explain the documented correlation between high intratumor heterogeneity and worse outcomes in conventional therapy. 32, 36, 37 For targeted therapy to cure a cancer in the context of subclonal evolution (Fig. 1) , all subclones need to contain the target (a truncal driver mutation with CCF 5 1), and no subclone can contain additional mutations or mechanisms that negate the therapy. Even if a target is identified for a patient, either of two likely consequences of intratumor heterogeneity-a low CCF for the target or a resistance mutation-would pose additional problems. Intratumor heterogeneity will almost always limit the effectiveness of targeted therapy.
If heterogeneity means that the target is not a truncal mutation, then targeted therapy will have no direct effect on cancer cells that lack it. A low MAF or CCF for a driver mutation can identify targets that are likely to fail, yet it is almost impossible, from a single pretreatment tumor sample, to assure that a target is truncal with CCF 5 1. 29 Having a target with CCF 5 1 is insufficient for targeted therapy success. By the time a tumor has reached the 10 9 cells necessary to be clinically detectable, some subclone will almost certainly contain a resistance mutation. Bozic and Nowak 38 estimate that a radiographically detectable tumor may have at least 10 resistant subclones, each providing a different resistance mechanism. So even if targeted therapy initially leads to clinical remission, resistant subclones will likely result in recurrence. This initial response followed by regrowth is common with targeted therapy. 6, 38, 40 Supporting this failure mechanism, earlier melanoma progression times after targeted therapy tended to occur in patients whose resistance mutations had sufficiently high MAF values to be detected in pretreatment tumors. 41 Although combination therapies provide hope that a subclone evading 1 therapy is unlikely to evade another, tumor genetic diversity also limits their effectiveness, because combinations face the same challenges as individual therapies. Diversity among tumors in terms of driver mutations is a major obstacle. If, as noted above, not even 10% of patients can be matched with a single targeted therapy based on the current catalog of driver mutations, then only a small percentage will likely have more than 1 identified target. Diversity within a tumor will limit the effect of combination therapy if some subclones lack the targets or if any subclone has mutations that provide resistance to the combination. Combined resistance might be a significant problem with a large tumor burden in patients with metastatic disease. 42 Combination therapies can also fail because of improper timing of administration. For example, if a single agent is used until recurrence is observed and then replaced with a second agent, then progeny of a subclone with resistance to the first agent might have time to develop resistance to the second agent before it is used. 42 
Challenges to Immunotherapy
It is possible that large numbers of neoantigens might help to overcome intratumor heterogeneity. Indeed, the best therapeutic responses to inhibition of immune checkpoints have been in tumors with high mutation frequencies and high neoantigen burdens. [43] [44] [45] However, mutation frequencies and intratumor heterogeneity are not the same. 32, 33 A recent report distinguished neoantigen numbers from heterogeneity in responses to immune-checkpoint blockade. 45 Neoantigens shared among all cancer cells (truncal mutations) provided the best targets. Those authors could not detect immune responses to subclonal antigens, noting that immune responses to subclonal antigens also would not target all tumor cells. Furthermore, it has now been demonstrated that subclonal mutations alter antigen presentation, making a subclone resistant to immune attack. 46 Thus intratumor heterogeneity likely poses challenges for immunotherapy similar to those observed for targeted therapy
MEETING THE CHALLENGES OF TUMOR GENETIC DIVERSITY
Now that the challenges posed by genetic diversity among and within tumors are clear, both types of diversity must thoroughly inform oncologic research and practice. To account for and understand diversity, clinical trials, genomic studies, and projects that combine clinical and genomic data need to directly examine diversity. Fundamental research on the mechanisms that generate and maintain intratumor heterogeneity may point to novel therapeutic approaches that exploit that type of diversity.
Clinical Trials
The NCI-MATCH trial, other basket trials, and trials of new agents do take diversity among tumors into account, because they use patient-specific driver mutations to match patients with agents. However, clinical trials have not yet incorporated diversity within tumors into trial design and interpretation.
Intratumor heterogeneity complicates the interpretation of responses to therapy. The initial response of a tumor to an agent may roughly represent the fraction of cancer cells in the tumor that both contain the intended target and are not resistant. The 30% decrease in greatest lesion dimensions for a partial response under Response Evaluation Criteria in Solid Tumors (RECIST) criteria 47 is an approximately 66% decrease in tumor volume. Thus a tumor with CCF 5 0.5 for the target might not produce a partial response even if the drug is completely active on the cells that do contain the target or if there is a high CCF for resistance mutations. Conversely, the dramatic and maintained effects of drugs in "exceptional responders" 48 may represent not only the unique oncogene addictions of their tumors but also a lack of subclones with resistance. Similarly, responders to induction chemotherapy, who can have better survival than nonresponders, 49 ,50 may be patients whose tumors have lower intratumor heterogeneity. Time to progression may be a measure of the size of resistant subclones rather than any inherent property of the drug-target combination, as suggested both by theoretical 42 and observational 41 studies. Without knowing the underlying intratumor genetic heterogeneity, it will be difficult to assign the mechanism of failure.
Because both initial responses to therapy and times to progression may represent heterogeneity rather than the intrinsic efficacy of therapy, it makes little sense to ignore heterogeneity in clinical trials. Studies of new agents might be performed best on patients who have homogeneous tumors with high target CCFs, based on pretreatment genomic analysis; alternatively, patients might be stratified by pretreatment tumor heterogeneity or target CCFs. Interpretation of clinical responses should incorporate information about heterogeneity to tease out responses related to the therapeutic target from those representing a consequence of heterogeneity.
Genomic Studies
Large-scale genomic studies to discover more drivers, combined with studies on the cellular processes those drivers affect, would help meet the challenge of genetic diversity among tumors. This means distinguishing driver mutations with very low prevalence, down to just a small percentage among patients' tumors, from passenger mutations. Lawrence et al 51 estimate that up to 5000 tumors of each type, a scale 10 times that attempted by TCGA, 1 are required before most driver mutations present in only 2% of tumors can be identified. Further basic science and translational work will be needed to match these low-prevalence drivers to targetable effects on cellular pathways. Genomic analysis of recurrent and metastatic tumors 46, 52 or of circulating cell-free tumor DNA 53, 54 provides a similar opportunity to identify resistance mutations. Even if resistance mutations are undetectable in a primary tumor because of low CCFs, subclone selection through therapy will likely lead to detectable high CCFs in recurrences. Genomic analysis also can assess intratumor heterogeneity, providing critical information generally unavailable thus far for translational or clinical work. Unfortunately, some recent genomic analyses use methods that hinder all of these approaches to addressing tumor diversity, preselecting extremely restricted portions of the genome through hybridization before NGS. Judicious preselection allows many more samples to be sequenced or analyzed at higher sequencing depth at the same cost as whole-genome sequencing. 55 For example, whole-exome sequencing, in which approximately 30 million bases (MB) covering nearly 20,000 protein-coding genes are preselected, has allowed remarkable advances in genomics at reasonable cost. 56 Many recent studies, however, have restricted genomic coverage much further, to just a few hundred known cancer genes. 37, 52, [57] [58] [59] [60] Whatever the economic advantages of sequencing a small panel of cancer genes, it does not foster the discovery of unknown driver mutations or resistance mechanisms. It also makes assessment of intratumor heterogeneity less reliable. A tumor will only have mutations in a few known cancer genes, whereas assessing its heterogeneity requires MAF values for many mutated loci. Illustrating this difficulty, when Pereira et al calculated tumor MATH values from sequencing 173 genes, approximately one-third of tumors did not even meet their low threshold of having 5 mutated loci to be eligible for MATH analysis. 37 Nevertheless, many data in the new NCI Genomic Data Commons (GDC) 61 are now in a highly restricted gene panel from Foundation Medicine. 62 Although having such genomic data readily available is an advance in many respects, it does little to address issues central to tumor genetic diversity. Furthermore, current GDC specifications do not require reporting the MAF values needed to assess heterogeneity. 63 Genomic data need both wide genome coverage and MAF values to support progress against the challenges of tumor genetic diversity.
Repositories Combining Clinical and Genomic Data
Repositories that link patients' clinical and genomic data, like that begun by TCGA and continued in the NCI GDC, could be extremely valuable for understanding tumor genetic diversity as well as other issues in oncology. Such repositories will be even more useful if the clinical and genomic data are further linked to biobanks of associated tissue specimens, as in the multi-institutional Oncology Research Information Exchange Network (ORIEN). 64 Genomic and clinical data from controlled trials provide advantages of uniform treatment and patient populations, clinical record quality, and follow-up. Comprehensive repositories of representative samples of patients not in trials could provide a solid basis for developing and testing new hypotheses relating to the standard-of-care cancer therapy that most patients still receive as research on new therapies continues. Design and oversight of these repositories, however, must take tumor genetic diversity into account, because both patient clinical characteristics and therapy choices would be expected to influence the relations of particular driver mutations 7 and intratumor heterogeneity 32, 36 to outcome. Much about repository planning can be learned from experience with TCGA. Its emphasis on acquiring many tumor samples 65 evidently led to a tradeoff, so that only minimal accompanying clinical data were required. Missing clinical data from patients with HNSCC in TCGA rendered us unable to address critical issues like the relation of heterogeneity to outcome in patients who underwent surgical tumor excision without receiving adjuvant therapy. 32 Also, the multiple types of analyses envisioned by TCGA placed a premium on having large frozen tumor samples. Patients in TCGA thus under-represented lower stages of HNSCC, so we were unable to resolve whether heterogeneity increases with T-classification. 32 Because tumors collected more recently are presumably from well designed genomic studies that had extensive clinical data, there is no reason for continued incomplete clinical annotation. Furthermore, with many genomic analyses now possible on standard formalinfixed, paraffin-embedded pathology specimens, 66 underrepresentation of lower stage disease can likely be rectified. Repositories might also greatly accelerate progress if their clinical data included information difficult or impossible to obtain from current databases 67 on outpatient therapy, recurrences, local versus distant failures, and diseasespecific survival.
Unfortunately, the structure of the new GDC has not yet moved far enough toward comprehensiveness in either case representation or clinical data. The open invitation to researchers to submit data to the GDC 68 may result in samples of convenience, with their inherent difficulties in interpretation, rather than representative sets of linked genomic and clinical data. More distressing, the current version of the GDC clinical data dictionary does not require information on therapy, 69 without which few clinically reliable conclusions can be drawn regardless of how much genomic data are provided.
The centralized oversight of the new US Moonshot could make a dramatic difference in clinical-genomic repositories. It could seek out representative samples of tumors, providing support for genomic analysis and clinical data acquisition, and extra support for efforts directly related to assessing heterogeneity, such as collection and analysis of multiple portions of individual tumors. It could condition funding for genomic analyses on sharing extensive, regularly updated, and audited clinical data. Similar to how the early TCGA commitment to genomic analysis 70 fostered genomic technology, a large-scale commitment by the Moonshot to automated parsing of clinical records could foster the development of improved technologies to turn clinical electronic records into useful research data, amplifying the value of associated genomic data.
Targeting Mechanisms Underlying Intratumor Heterogeneity
Although intratumor genetic heterogeneity poses challenges to current therapies, it might provide novel therapeutic targets. There are already intriguing hints about how this heterogeneity could be exploited once further research documents how it is established and maintained.
First, a tumor's heterogeneity represents diversity produced by mutations followed by the selection of clones with high fitness. This requires just enough, but not too much, generation of diversity. 71 It might be possible to tip that balance in a heterogeneous tumor toward genetic instability, diminishing cancer-cell survival. 72 Second, selection could be exploited with a view toward making a tumor more homogeneous and treatable. If therapy selects a particular subclone, then the posttreatment tumor should initially become more homogeneous than the pretreatment primary. 73 Data from Gerlinger et al 29, 74 suggest that tumors from patients who received treatment with everolimus were more homogeneous than tumors from untreated patients. Such genetic consolidation of tumors might help identify subclonespecific targets not identified in pretreatment biopsies, providing consolidation therapy for pharmaceutical rather than surgical follow-up.
Third, continuing evolution within a tumor represents subclones that both compete and cooperate; and either process might be targeted if the mechanisms were better understood. For example, a model of 3-dimensional tumor growth suggests that subclones with greater cellular migratory capacity outcompete other subclones by being better able to reach tumor regions that favor cell division over cell death. 75 Migratory activity thus might provide a therapeutic target. Cooperation among subclones might also provide therapeutic targets. In mouse models, a small subclone can enhance growth and invasiveness of other cancer cells through the microenvironment. 76 Targeting those subclones or inhibiting their influence could provide a novel therapeutic approach. Research on competition and cooperation among subclones, currently in early stages, might provide many other ways to take advantage of the mechanisms underlying intratumor heterogeneity.
CONCLUSION
Although genetic diversity both among and within tumors poses substantial challenges to personalized medicine, including targeted and immunotherapy, these challenges may be met if diversity is directly addressed. Identifying more driver mutations and how they affect cellular processes will address challenges from diversity among tumors. Assessing diversity within tumors will allow the evaluation of its effects. A better understanding of intratumor heterogeneity should provide new therapeutic targets. Expanded and improved combinations of genomic and clinical data will facilitate this and many other types of cancer research.
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